NYSE · LLY
Eli Lilly and Company
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
Loading market information…
NASDAQ · BTSGU · USD
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
BrightSpring Health Services, Inc. Tangible Equity Unit’s quoted price sits in the upper half of its reported 52-week range, 22.39% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
BrightSpring Health Services, Inc. Tangible Equity Unit’s forward annual dividend is $3.38 per share, paid quarterly. The forward yield is 1.7% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
BrightSpring Health Services, Inc. Tangible Equity Unit’s next earnings report is currently expected on Oct 30, 2026, with estimated earnings per share of $0.47. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow BrightSpring Health Services, Inc. Tangible Equity Unit’s reporting calendar.
THE COMPANY BEHIND THE TICKER
BrightSpring Health Services, Inc. is a U.S.-based healthcare organization that provides a comprehensive suite of services directly to individuals in their homes and local communities. The company's primary focus is on delivering pharmacy and direct patient care services, encompassing both clinical treatment and supportive assistance. These services are specifically tailored for populations covered by Medicare, Medicaid, and private insurance. Care is administered by a network of clinical providers and pharmacists. Established in 1974, the firm is headquartered in Louisville, Kentucky, and adopted its current name, BrightSpring Health Services, Inc., in May 2021, having previously been known as Phoenix Parent Holdings Inc.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:25 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| $3.15B+5.3% vs estimate |
| Q1 2025 | May 2, 2025 | $0.19+108.86% vs estimate | $2.88B+6.11% vs estimate |
|---|
| Q4 2024 | Mar 6, 2025 | $0.22+3.82% vs estimate | $3.05B+1.38% vs estimate |
|---|
| Q4 2024 | Jan 20, 2025 | $0.11-28.53% vs estimate | $2.91B+6.93% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
$275.20+$4.16 (+1.53%)
Johnson & Johnson’s quoted price sits in the upper half of its reported 52-week range, 2.09% below the high.
$290.97+$4.98 (+1.74%)
AbbVie Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.55% below the high.
$410.91+$3.81 (+0.94%)
UnitedHealth Group Incorporated’s quoted price sits in the upper half of its reported 52-week range, 10.99% below the high.
$146.33+$5.40 (+3.83%)
Merck & Co., Inc.’s quoted price sits in the upper half of its reported 52-week range, 6.75% below the high.
$541.92+$8.56 (+1.6%)
Chemed Corporation’s quoted price sits in the upper half of its reported 52-week range, 3.61% below the high.
$29.67+$0.35 (+1.19%)
Hims & Hers Health, Inc.’s quoted price sits in the lower half of its reported 52-week range, 38.62% below the high.
$13.64+$0.25 (+1.83%)
LifeStance Health Group, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.11% below the high.
